CAR T-Cell therapy Market

CAR T-Cell Therapy Market Research, 2031

The global car t-cell therapy market size was valued at $1.7 billion in 2021, and is projected to reach $6.1 billion by 2031, growing at a CAGR of 13.5% from 2022 to 2031. Chimeric antigen receptor (CAR) T-cell therapy is a new type of cancer treatment, in which   healthcare professionals change to T-cells in the lab and then infuse into the body of cancer patient, so they can find and destroy cancer cells. CAR T-cell therapy is a method of training the immune system to recognize cancerous cells. It is called as gene or cell therapy. CAR T-cell therapy is used to enhance the immune response against cancerous cells.

The COVID-19 pandemic had a negative impact on the CAR T-Cell therapy market because priority is given to COVID-19 patient for treatment. Discovery and development of CAR T-cell therapy medicine slowed down during the pandemic but did not stop. The significant reduction in clinical trials due to strict government guidelines against COVID-19, resists the growth of CAR T-cell therapy market. Decline in people transit, closing of borders, and confinement of the population impacted the supply chains of these life-saving medical products in the CAR T-cell therapy market.

Leukemia is a type of cancer, which affects the production and function of blood cells. This causes swollen lymph nodes, recurrent nosebleeds, tiredness, frequent infections, weight loss, bleeding, and bone pain. Lymphoma is a cancer of the lymphatic system, which is part of the body's germ-fighting network. Lymphoma develops in lymphocytes, which are a type of white blood cell. These cells help to fight against infectious diseases in the body and play an essential role in the body’s immune defenses.

The benefits of CAR T-cell therapies over conventional drugs, include the destruction of cancer cells using patients' immune system, early recovery, and shortened treatment time. In addition, CAR T-cell therapy survives for a long time in the body, as they have the ability to recognize and target cancer cells even if the cancer relapses. The CAR T-cell therapy is mainly used for the treatment of lymphoma, acute lymphocytic leukemia, and multiple myeloma blood cancer. Owing to its various advantage over conventional drugs, the CAR T-cell therapy products witness a high adoption rate; which eventually leads to the growth in the CAR T-cell therapy market.

The major factors that drive the CAR T-cell therapy market is surge in demand for ideal therapeutics for treatment of cancer, increase in prevalence of cancer, favorable reimbursement policies in some countries regarding CAR T-cell therapy medicine, and rise in awareness of CAR T-cell therapy medicine. The CAR T-cell therapy market is witnessing a rise, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, which are expected to offer lucrative opportunities for market expansion.

However, the sales of CAR T-cell therapy medicine have witnessed hindrances, owing to lack of skilled professionals for given CAR T-cell therapy in some developing and underdeveloped countries. Higher cost of the therapy also hampers the market growth.   Conversely, rise in awareness and increase in approval of new medicine of CAR T-cell therapy and promising drugs present in pipelines are anticipated to offer remunerative opportunities for the expansion during global CAR T-cell therapy market forecast period.

Rise in prevalence of multiple myeloma cancer and increase in incidences of lymphoma and leukemia lead to high adoption of CAR T-cell therapy product, which propel to market growth. For instance, according to the LEUKEMIA and LYMPHOMA SOCIETY, an estimated 34,920 new cases of myeloma (19,320 males and 15,600 females) were expected to be diagnosed in the U.S. in 2021 and an estimated 138,415 people in the U.S. are living with or in remission from myeloma. According to the LEUKEMIA and LYMPHOMA SOCIETY, in 2021, 61,090 people were expected to be diagnosed with leukemia in the U.S., and an estimated 397,501 people are living with or in remission from leukemia in the U.S.  

The COVID-19 outbreak is anticipated to have a negative impact on the market, as huge number of medical college and hospitals across the globe were restructured to increase the hospital capacity for patients diagnosed with COVID-19. The COVID-19 pandemic had a negative impact on the  market because priority is given to COVID-19 patient for treatment. Discovery and development of CAR T-cell therapy medicine slowed down during the pandemic but did not stop. The significant reduction in clinical trials due to strict government guidelines against COVID-19, resists the growth of CAR T-cell therapy market size. Decline in people transit, closing of borders, and confinement of the population impacted the supply chains of these life-saving medical products in the CAR T-cell therapy market share. Nonessential surgical procedures took a potential backlog and home setting care was preferred, owing to rapidly rising COVID-19 cases, as only elective emergency surgeries were performed.

Therefore, this is anticipated to slowdown in market growth during the ongoing pandemic. However, owing to the introduction of various COVID-19 vaccination, people can readily reach out to hospital and cancer treatment centers, due to which surge in the demand of CAR T-cell therapy is expected in the near future. The demand of CAR T-cell therapy medicine is expected to increase, owing to surge in the R&D activities, rapidly expanding clinical trial activities, and recent commercialization of CAR-T cell therapy. Thus, such development is anticipated to bring stabilization and drive the CAR T-cell therapy market growth.

The CAR T-cell therapy market is segmented into Indication, End user and Drug type.

The CAR T-cell therapy market is segmented on the basis of product type, indication, end user, and region. On the basis of product type, the market is classified into axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel,  and others. By indication, the market is segregated into lymphoma, acute lymphocytic leukemia, and others. Depending on end user, it is fragmented into hospitals and cancer treatment centers.

Region-wise, the market is analyzed across North America (the U.S. and Canada), Europe (Germany, France, UK  and rest of Europe), Asia-Pacific (Japan, China,  and rest of Asia-Pacific), and LAMEA (Latin America and Middle East and Africa)

Segment Review

By drug type, the axicabtagene ciloleucel segment was the highest revenue contributor to the market, owing to increase in adoption of (Yescarta) axicabtagene Ciloleucel medicine for treatment of relapsed or refractory large B-cell lymphoma, relapsed or refractory follicular lymphoma. The brexucabtagene autoleucel segment is expected to witness the highest CAGR during the forecast period, owing to rise in approval of CAR T-cell therapy medicine in different countries for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).  

On the basis of indication, the lymphoma segment generated maximum revenue in 2021, owing to higher number of approved CAR T-cell therapeutics for treatment of different form of lymphoma with large number of target population. The acute lymphocytic leukemia segment is expected to witness the highest CAGR during the forecast period, owing to increase in awareness of CAR T-cell therapeutics for treatment of acute lymphoblastic leukemia and expected launch of these drug for treatment of acute lymphoblastic leukemia regarding testing of blood cancer.

On the basis of end user, the hospitals segment was the highest revenue contributor to the market in 2021, owing to factors such as well-equipped operation theatre, higher buying power, and rise in patient admission. The cancer treatment centers segment is expected to witness the highest CAGR during the forecast period, owing to availability of a wide range of choice of treatment and increase in the number of cancer centers in some developing nations.

Depending on region, North America generated the highest revenue in 2021 owing to strong presence of key players and availability of approved therapeutics with higher adoption of CAR T cell therapies. Asia-Pacific is expected to witness the highest CAGR during the forecast period owing to rise in awareness regarding CAR T-cell therapy, expected launch of CART drugs, and rise in the number of target population.

The key players operating in the CAR T-cell therapy industry are Autolus, Bluebird Bio-Inc., Bristol-Myers Squibb, Caribou Biosciences Inc., Cartesian Therapeutics, Celgene Corporation, Cellectis, Celyad, Gilead Sciences, Inc. (Kite Pharma Inc.), Intellia Therapeutics, Juno Therapeutics, Merck & Co. Inc., Miltenyi Biotech, Novartis AG, Pfizer Inc., and Sorrento Therapeutics, Inc.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the car t-cell therapy market analysis from 2021 to 2031 to identify the prevailing car t-cell therapy market opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the car t-cell therapy market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global car t-cell therapy market trends, key players, market segments, application areas, and market growth strategies.

 CAR T-Cell therapy Market Report Highlights